Eli Lilly and Company $LLY Shares Sold by Altfest L J & Co. Inc.

Key Points

• Altfest L J & Co. Inc. reduced its stake in Eli Lilly by 8.0% in Q4, selling 1,109 shares and leaving 12,693 shares worth $13.641 million, which represents about 1.5% of its portfolio and is its 19th largest holding.
• Eli Lilly beat quarterly estimates with $7.54 EPS (vs. $7.48) and $19.29 billion in revenue (vs. $17.85 billion), a 42.6% year‑over‑year revenue increase, and set FY2026 guidance of $33.50–$35.00 EPS.
• Analysts' consensus is a Moderate Buy with an average price target of $1,224.59 (2 Strong Buy, 23 Buy, 4 Hold, 1 Sell), and several firms have recently adjusted targets upward (e.g., Wells Fargo to $1,280).

Altfest L J & Co. Inc. reduced its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,693 shares of the company's stock after selling 1,109 shares during the period. Eli Lilly and Company accounts for about 1.5% of Altfest L J & Co. Inc.'s portfolio, making the stock its 19th largest holding. Altfest L J & Co. Inc.'s holdings in Eli Lilly and Company were worth $13,641,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares in the last quarter. Steph & Co. increased its stake in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company's stock worth $30,000 after buying an additional 29 shares in the last quarter. 10Elms LLP increased its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares in the last quarter. Finally, Miller Global Investments LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $33,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on LLY. Berenberg Bank boosted their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a research note on Thursday, February 19th. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 6th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Zacks Research lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. Finally, Guggenheim dropped their price target on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,224.59.

Eli Lilly and Company Trading Down 1.8%

Shares of Eli Lilly and Company stock opened at $905.73 on Thursday. The firm has a market capitalization of $855.75 billion, a price-to-earnings ratio of 39.47, a PEG ratio of 1.07 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a 50 day moving average of $976.09 and a 200 day moving average of $979.89.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm's revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the prior year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly received another buy rating tied to its newly launched obesity pill, which analysts expect to be a global bestseller — this supports revenue upside from weight‑loss therapies. Eli Lilly Stock (LLY) Gets Another Buy Rating as Its Obesity Pill Hits the Market
• Positive Sentiment: Lilly agreed to acquire CrossBridge Bio for up to $300M, adding preclinical ADC technology to bolster oncology pipeline optionality and long‑term growth prospects. Lilly to acquire CrossBridge Bio for up to $300m
• Positive Sentiment: Distribution and access expand as digital care platform Shed adds Foundayo™ (Lilly’s oral GLP‑1 for weight management), which can help broaden patient uptake beyond specialty clinics. Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide
• Positive Sentiment: Lilly is licensing its TuneLab AI platform to partners (e.g., Vasa Therapeutics), highlighting additional revenue streams and R&D leverage from proprietary AI tools. Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform
• Neutral Sentiment: Macro/valuation commentary remains mixed — some bullish, long‑term price targets (e.g., Forbes piece on LLY to $2,000) reflect confidence in blockbuster drugs but are speculative. LLY Stock To $2,000?
• Neutral Sentiment: Market reports note the stock is down today despite broader market gains — a short‑term price action update for traders. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: Competitive risk is rising: Novo Nordisk’s new partnership with OpenAI to accelerate drug discovery reinforces its capability to close gaps in the weight‑loss market and may pressure Lilly’s market share and investor sentiment. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.